Regional Meetings 2017

Recently Approved and Emerging Strategies in the Management of Gastrointestinal Cancers: An Interactive Grand Rounds Series

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of Gastrointestinal Cancers. Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at or call (800) 233-6153.

Please click here to learn more about our Non-Small Cell Lung Cancer series or here to learn more about our Ovarian Cancer series.

Schedule of Events:

Friday, October 27, 2017
8:00 AM – 9:00 AM Education program

Johanna C Bendell, MD
SUNY Downstate Medical Center
Brooklyn, New York
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

This 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of gastrointestinal cancer and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Colorectal Cancer MODULE 2: Gastric Cancer MODULE 3: Hepatocellular Carcinoma MODULE 4: Integration of Novel Agents into the Treatment Algorithm

Each session will conclude with a 10-minute Q&A segment


Tanios Bekaii-Saab, MD
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Scottsdale, Arizona

Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Howard S Hochster, MD
Associate Director (Clinical Research)
Yale Cancer Center
Professor of Medicine, Yale School of Medicine
New Haven, Connecticut

Heinz-Josef Lenz, MD
Professor of Medicine and Preventive Medicine
J Terrence Lanni Chair in Cancer Research
Co-Director, USC Center for Molecular
Pathways and Drug Discovery
Keck School of Medicine, University of
Southern California
Associate Director of Adult Oncology
Co-Director, Colorectal Center
Scientific Director, Cancer Genetics Unit
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Bert H O’Neil, MD
Professor of Medicine
Director, Phase I and GI Malignancies Programs
Indiana University Simon Cancer Center
Indianapolis, Indiana

Philip A Philip, MD, PhD
Professor of Oncology and Medicine
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Project Chair

Neil Love, MD
Research To Practice
Miami, Florida

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancer.

Learning Objectives:

  • Appreciate the recent FDA approval of TAS-102, and develop an evidence-based approach to integrate this agent into the management of metastatic colorectal cancer.
  • Recognize the unique mechanism of action of, available clinical trial data with and clinical indications for the use of MM-398 for patients with treatment-refractory metastatic pancreatic cancer, and use this information to guide nonresearch treatment planning.
  • Consider available clinical research data documenting the efficacy of ramucirumab in metastatic colorectal and gastric or gastroesophageal junction cancers, and discern how this agent can be optimally integrated into clinical practice for patients with these diseases.
  • Educate patients with select gastrointestinal (GI) cancers regarding the potential side effects of recently approved agents, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
  • Develop an understanding of emerging Phase III efficacy data with and the potential clinical role of regorafenib in preparation for its potential introduction into the practical management of relapsed/refractory hepatocellular carcinoma.
  • Appraise the biologic rationale for and available clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in the treatment of select GI cancers.
  • Recall available and emerging data with other investigational agents currently in Phase III testing for various GI cancers, and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

These activities are supported by educational grants from Boston Biomedical Pharma Inc, Exelixis Inc, Lilly, Merck and Merrimack Pharmaceuticals Inc.